Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who
have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled.
Enrollment will be monitored to ensure that not all subjects are enrolled based on rising
prostate specific antigen (PSA) criterion only.
Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks
for 12 weeks (total dose of 600 mg).